Suppression of hematologic and neurological expression-1 promotes tumor immunity by regulating the GSKβ-PD-L1 Axis

Despite various efforts have been made to prolong the liver patients’ survival rates, liver cancer is still one of the malignancies with a high mortality rate in worldwide. The clinical efficacy of anti-PD-1/PD-L1 treatments has been investigated associated with PD-L1 levels, but, the relationship between hematologic and neurological expression 1(HN1) and immunosuppressive molecules PD1 and PD-L1 in liver cancer is not clearly understood. Here, we reported for the first time that HN1 acts as a novel negative regulator of PDL1, whose abnormal expression plays a crucial role in cancer immune evasion in hepatocellular carcinoma. This study establishes a key molecular link between targeted therapy and immune surveillance and identifies that combination therapy with HN1 inhibition and an anti-PD-1 antibody has much better antitumor efficacy than either monotherapy in hepatocellular carcinoma. This is the full abstract presented at the American Physiology Summit 2023 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.